{"analyses":[{"ciLowerLimit":"0.331","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.700","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.482","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% confidence interval is not evaluable due to high censoring.","groupId":"OG000","lowerLimit":"17.31","upperLimit":"NA","value":"24.84"},{"groupId":"OG001","lowerLimit":"8.77","upperLimit":"16.76","value":"11.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally, BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W, plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg\\] IV) or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)"}],"paramType":"MEDIAN","populationDescription":"ITT Population: All randomized participants, even if a participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol. Participants were analyzed according to the treatment arm they were assigned to regardless of what actual treatment they received. Participants censored: TRT A: 98, TRT B:45.","reportingStatus":"POSTED","timeFrame":"Baseline to Progressive Disease or Death from Any Cause Up to 31 Months","title":"PFS by BICR (With or Without Pembrolizumab)","type":"PRIMARY","unitOfMeasure":"Months"}